Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
What you need to know about desalination, a growing source of drinking water- The Response to Independence from the rat race: Methodologies for Creating Financial momentum
- I traveled to 13 countries in 2025. This small island nation surprised me the most.
- Instructions to Figure out the Various Phases of Cellular breakdown in the lungs
- Canada Awards C$1.5 Billion Defense Contracts to L3Harris, Airbus
- Miley Cyrus details her fear of paper, says fiancé Maxx Morando opens their packages outside: 'That's really why I got engaged'
- 5 things for parents to know about changes to kids vaccine schedule
- Gulf countries continue to face Iran attacks as criticial energy infrastructure at risk
- At least 30 killed in attack on Nigeria village
